



27 June 2019
EMA/368428/2019
Human Medicines Evaluation Division

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product

Keytruda/ pembrolizumab	
Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s) in the Community Register of Medicinal Products:	See Annex A

Marketing Authorisation Holder (MAH):

Name and address of the MAH:	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem NETHERLANDS
------------------------------	---

Procedure

Procedure number:	EMA/H/C/003820/II/0071
-------------------	------------------------

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

-the development of this product has complied with all measures in the agreed paediatric investigation plan P/0043/2018. All studies in the agreed paediatric investigation plan P/0043/2018 were conducted after the entry into force of that Regulation,

-the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan P/0043/2018 is included in the technical dossier.

